Parkinson Subtypes Progress Differently in Clinical Course and Imaging Pattern

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Eggers, Carsten ^a   Pedrosa, David J ^a   Kahraman, Deniz ^a   Maier, Franziska ^a   Lewis, Catharine J ^a   Fink, Gereon R ^a,b   Schmidt, Matthias ^a   Timmermann, Lars ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; IOFLUPANE I 123; MADOPAR LT; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; IN VIVO STUDY; MALE; PARKINSON DISEASE; PUTAMEN; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84867313463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046813     Document Type: Article

References (40)

1. Young AB PJ, editor (2002) Biochemical and functional organization of the basal ganglia. In: Jankovic JJ, tolosa E (eds). Philadelphia, USA: Lippincott Williams and Wilkins. pp 1-10.
2. Timmermann L, Gross J, Dirks M, Volkmann J, Freund HJ, et al. (2003) The cerebral oscillatory network of parkinsonian resting tremor. Brain 126: 199-212.
3. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, et al. (1990) Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40: 1529-1534.
4. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A, (2009) Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 73: 206-212.
5. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, et al. (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56: 334-337.
6. Jankovic J, Kapadia AS, (2001) Functional decline in Parkinson disease. Arch Neurol 58: 1611-1615.
7. Marras C, Rochon P, Lang AE, (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59: 1724-1728.
8. Kaufman MJ, Madras BK, (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 9: 43-49.
9. Niznik HB, Fogel EF, Fassos FF, Seeman P, (1991) The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 56: 192-198.
10. Spiegel J, Hellwig D, Samnick S, Jost W, Mollers MO, et al. (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 114: 331-335.
11. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, et al. (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15: 503-510.
12. Breit S, Reimold M, Reischl G, Klockgether T, Wullner U, (2006) [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm 113: 187-193.
13. Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, et al. (1992) Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 42: 1554-1560.
14. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L, (2011) Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT Single photon emission computed tomography. Mov Disord Feb 15 26(3): 416-23.
15. Hoehn MM, Yahr MD, (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
16. Fahn S. Elton RL mot UDC, editor (1987) The Unified Parkinson's disease Rating Scale. Florham Park (NJ): McMillan Healthcare Information. 153-163, 293-304 p.
17. Daniel SE, Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39: 165-172.
18. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, et al. (2008) Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 14: 93-101.
19. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, et al. (2005) Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76: 343-348.
20. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, et al. (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309.
21. Koch W, Radau PE, Hamann C, Tatsch K, (2005) Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 46: 1109-1118.
22. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, et al. (2002) European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 29: BP30-35.
23. Morton RJ, Guy MJ, Clauss R, Hinton PJ, Marshall CA, et al. (2005) Comparison of different methods of DatSCAN quantification. Nucl Med Commun 26: 1139-1146.
24. Friston K (2007) Statistical Parametric Mapping: The Analysis of Functional Brain Images. Amsterdam: Elsevier/Academic Press.
25. Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, et al. (2007) Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 48: 1459-1467.
26. Job DE, Whalley HC, McConnell S, Glabus M, Johnstone EC, et al. (2002) Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry. Neuroimage 17: 880-889.
27. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, et al. (2001) [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 108: 1011-1019.
28. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, et al. (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 294-298.
29. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, et al. (2001) Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16: 608-615.
30. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, et al. (2009) Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 132: 2970-2979.
31. Jellinger KA (1999) Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56: 1-29.
32. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, et al. (2009) A clinico-pathological study of subtypes in Parkinson's disease. Brain 132: 2947-2957.
33. Brown RG, Landau S, Hindle JV, Playfer J, Samuel M,et al. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry 82: 803-809.
34. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ,et al. (epub 2010/06/11) The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 25: 969-978.
35. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF, (2009) The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 15: 379-382.
36. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, (2003) Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60: 601-605.
37. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, et al. (2006) Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77: 585-589.
38. Zetusky WJ, Jankovic J, Pirozzolo FJ, (1985) The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 35: 522-526.
39. Hariz GM, Forsgren L Activities of daily living and quality of life in persons with newly diagnosed Parkinson's disease according to subtype of disease, and in comparison to healthy controls. Acta Neurol Scand 123: 20-27.
40. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, et al. (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10: 36-43.